Stanford inventors have identified a therapeutic CRISPR-based gene editing strategy that restores expression of Forkhead Box Protien 3 (FOXP3) isoforms that are disrupted in patients with Immunedysregulation, Polyendocrinopathy, Enteropathy X-linked Syndrome (IPE